Article
AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia.
Experimental hematology - 1 Aug 2010
Barbarroja Nuria, Torres Luis-Arístides, Rodriguez-Ariza Antonio, Valverde-Estepa Araceli, Lopez-Sanchez Laura Maria, Ruiz-Limon Patricia, Perez-Sanchez Carlos, Carretero Rosario Maria, Velasco Francisco, López-Pedrera Chary
Abstract excerpt
OBJECTIVE: Aberrant activation of tyrosine kinase receptors is frequently observed in acute myelogenous leukemia (AML). Moreover, activating mutations of the fms-like tyrosine kinase 3 (FLT3) receptor can be found in approximately 30% of patients, thereby representing one of the most frequent single genetic alterations in AML. AEE788, a novel dual receptor tyrosine kinase inhibitor of endothelial growth factor...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
